Dr. Soliman Abdul Kader Fakeeh Hospital (4017.SR) Earnings Analysis
Dr. Soliman Abdul Kader Fakeeh Hospital (4017.SR) next reports earnings on 2026-08-12, consensus EPS 0.26 SAR. Last quarter (2026-02-25) it beat with EPS 0.31 SAR vs 0.31 SAR est (0%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 31.09.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 4017.SR next report earnings?
| Next earnings date | 2026-08-12 |
|---|---|
| Consensus EPS estimate | 0.26 SAR |
| Revenue estimate | 0.86B |
4017.SR earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-25 | 0.31 SAR | 0.31 SAR | 0% | Beat |
| 2025-06-30 | 0.36 SAR | n/a | n/a | n/a |
| 2025-05-12 | 0.3139 SAR | n/a | n/a | n/a |
| 2025-03-05 | 0.32 SAR | n/a | n/a | n/a |
| 2024-11-07 | 0.4396 SAR | n/a | n/a | n/a |
Beat rate: 1/1 (100%) over reported quarters with consensus data.
4017.SR valuation and analyst view
| Trailing P/E | 31.09 |
|---|---|
| Trailing EPS | 1.115 SAR |
| Price / book | 2.49 |
| Dividend yield | 0.95% |
| Market cap | 7.91B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Dr. Soliman Abdul Kader Fakeeh Hospital (4017.SR)'s next earnings date?
Dr. Soliman Abdul Kader Fakeeh Hospital is next scheduled to report on 2026-08-12, with a consensus EPS estimate of 0.26 SAR and revenue estimate of 0.86B.
Did 4017.SR beat earnings last quarter?
In its 2026-02-25 report, 4017.SR posted EPS of 0.31 SAR versus a 0.31 SAR estimate — a beat of 0%.
What is 4017.SR's earnings track record?
Over the last 1 reported quarters with consensus data, 4017.SR beat estimates 1 times (100%).
What is 4017.SR's current P/E ratio and EPS?
4017.SR trades at a trailing P/E of 31.09 on trailing EPS of 1.1147652130434782 SAR.
What do analysts rate 4017.SR?
4017.SR has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.